159 related articles for article (PubMed ID: 32897570)
1. Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.
Gueneau de Mussy P; Sidharta PN; Wuerzner G; Maillard MP; Guérard N; Iglarz M; Flamion B; Dingemanse J; Burnier M
Clin Pharmacol Ther; 2021 Mar; 109(3):746-753. PubMed ID: 32897570
[TBL] [Abstract][Full Text] [Related]
2. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
3. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
Sidharta PN; Dingemanse J
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
[TBL] [Abstract][Full Text] [Related]
4. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
Fontes MSC; Dingemanse J; Sidharta PN
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
[TBL] [Abstract][Full Text] [Related]
5. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.
Verweij P; Danaietash P; Flamion B; Ménard J; Bellet M
Hypertension; 2020 Apr; 75(4):956-965. PubMed ID: 32063059
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
[TBL] [Abstract][Full Text] [Related]
7. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
Sidharta PN; Ulč I; Dingemanse J
Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
[TBL] [Abstract][Full Text] [Related]
8. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
Lindegger N; Sidharta PN; Reseski K; Dingemanse J
Pulm Pharmacol Ther; 2014 Oct; 29(1):41-8. PubMed ID: 24813561
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension.
Brussee JM; Sidharta PN; Dingemanse J; Krause A
J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):243-252. PubMed ID: 38332190
[TBL] [Abstract][Full Text] [Related]
10. First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis.
Hunter RW; Moorhouse R; Farrah TE; MacIntyre IM; Asai T; Gallacher PJ; Kerr D; Melville V; Czopek A; Morrison EE; Ivy JR; Dear JW; Bailey MA; Goddard J; Webb DJ; Dhaun N
Hypertension; 2017 Jul; 70(1):192-200. PubMed ID: 28507171
[TBL] [Abstract][Full Text] [Related]
11. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
Sidharta PN; Fischer H; Dingemanse J
Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
[TBL] [Abstract][Full Text] [Related]
12. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.
Fontes MSC; Dingemanse J; Halabi A; Tomaszewska-Kiecana M; Sidharta PN
Sci Rep; 2022 Nov; 12(1):19067. PubMed ID: 36352054
[TBL] [Abstract][Full Text] [Related]
13. Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects.
Sidharta PN; Dingemanse J
Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):227-234. PubMed ID: 31773427
[TBL] [Abstract][Full Text] [Related]
14. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
McCoy EK; Lisenby KM
J Cardiovasc Pharmacol; 2021 Jun; 77(6):699-706. PubMed ID: 34001723
[TBL] [Abstract][Full Text] [Related]
15. A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.
Bartolucci R; Dosne AG; Csonka D; Pérez-Ruixo JJ; Magni P; Poggesi I
Clin Pharmacokinet; 2021 Dec; 60(12):1605-1619. PubMed ID: 34159557
[TBL] [Abstract][Full Text] [Related]
16. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
Danaietash P; Verweij P; Wang JG; Dresser G; Kantola I; Lawrence MK; Narkiewicz K; Schlaich M; Bellet M;
J Clin Hypertens (Greenwich); 2022 Jul; 24(7):804-813. PubMed ID: 35686330
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
Sidharta PN; van Giersbergen PL; Dingemanse J
J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
[TBL] [Abstract][Full Text] [Related]
18. Aprocitentan and the endothelin system in resistant hypertension.
Clozel M
Can J Physiol Pharmacol; 2022 Jul; 100(7):573-583. PubMed ID: 35245103
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.
Packer M; McMurray JJV; Krum H; Kiowski W; Massie BM; Caspi A; Pratt CM; Petrie MC; DeMets D; Kobrin I; Roux S; Swedberg K;
JACC Heart Fail; 2017 May; 5(5):317-326. PubMed ID: 28449795
[TBL] [Abstract][Full Text] [Related]
20. Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.
Juif PE; Dingemanse J; Voors-Pette C; Ufer M
AAPS J; 2020 Aug; 22(5):103. PubMed ID: 32748293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
